To test the safety and immunogenicity of a high-titered preparation of ALVAC-HIV vCP205 in
both high-risk and low-risk persons and to evaluate variations in dosing schedule, we …

Background In clinical trials, canarypox ALVAC–human immunodeficiency virus (HIV)
vaccines have been shown to elicit human HIV–specific cytotoxic T lymphocyte (CTL) …

Background: A goal of T-cell HIV vaccines is to define the correlation between a vaccine-
induced immune response and protection from HIV infection. We conducted a phase 2 trial …

Background: The first multicenter, international National Institutes of Allergy and Infectious
Diseases (NIAID)-sponsored HIV vaccine trial took place in Brazil, Haiti, Peru and Trinidad …

In order to boost immune responses in persons in whom highly active antiretroviral therapy
(HAART) was initiated within 120 days of the onset of symptoms of newly acquired human …

Objective: Evaluate immunogenicity and clinical efficacy of two immunization strategies with
the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients …

Background The development of a safe and effective vaccine against the human
immunodeficiency virus type 1 (HIV-1) is critical to pandemic control. Methods In a …

Objective: To determine the ability of live attenuated canarypox virus expressing HIV
antigens to induce CD8+ cytotoxic T-cell responses and to prime for neutralizing antibody …

The efficacy of a recombinant human immunodeficiency virus (HIV) type 2 canarypox
(ALVAC HIV-2) vaccine candidate given alone or in combination with HIV-2 envelope gp125 …

This open single-arm study evaluated whether the administration of an HIV-recombinant
canarypox vaccine (vCP1433) in highly active antiretroviral therapy (HAART)-treated …